Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.

Aberrant DNA methylation of promoter CpG islands is associated with transcriptionally repressive heterochromatin in neoplasia. The dynamics of this epigenetic process in mediating the transition from an active to an inactive state of transcription remains to be elucidated, however. Here, we used the methylation-specific oligonucleotide microarray to map the methylation patterns of a CpG island, located within the promoter and the first exon regions of RASSF1A, in normal breast tissue controls, primary tumors, and breast cancer cell lines. Oligonucleotide pairs, spaced along the CpG island region, were designed to discriminate between methylated and unmethylated alleles of selected sites. The methylation-specific oligonucleotide data indicate that the majority of test samples show widespread methylation in the first exon of RASSF1A. In contrast, the promoter area was usually undermethylated in normal controls and in 32% of the primary tumors tested, whereas the rest of the primary tumors and breast cancer cell lines showed various degrees of methylation in the region. Methylation profiling of individual tumors further suggest that DNA methylation progressively spreads from the first exon into the promoter area of this gene. Functional analysis indicates that increased density of RASSF1A promoter methylation is associated with altered chromatin, marked by a depletion of acetylated histones and methylated histone 3-lysine 4 and an enrichment of methylated histone 3-lysine 9 in the studied area. The combination of these epigenetic modifications may engender a stable silencing of the gene in breast cancer cells. Thus, this study underscores the importance of detailed mapping of methylation patterns within a CpG island locus that may provide insights into the progressive nature of aberrant DNA methylation and its relationship with transcriptional silencing during the neoplastic process.

[1]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[2]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Laird,et al.  COBRA: a sensitive and quantitative DNA methylation assay. , 1997, Nucleic acids research.

[4]  J. Kwong,et al.  High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.

[5]  A. Bird,et al.  Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. , 1994, Genes & development.

[6]  J. Herman,et al.  p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.

[7]  Huidong Shi,et al.  Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. , 2002, Genome research.

[8]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[9]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[10]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[11]  A. Bird CpG-rich islands and the function of DNA methylation , 1986, Nature.

[12]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[13]  M. Matsuoka,et al.  Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. , 2000, Cancer research.

[14]  T. Huang,et al.  Methylation profiling of CpG islands in human breast cancer cells. , 1999, Human molecular genetics.

[15]  G. Yang,et al.  Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. , 2001, Cancer research.

[16]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[17]  S. Clark,et al.  Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. , 1997, Cancer research.

[18]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Clark,et al.  A Distinct Sequence (ATAAA) n Separates Methylated and Unmethylated Domains at the 5′-End of theGSTP1 CpG Island*210 , 2000, The Journal of Biological Chemistry.

[20]  J. Issa,et al.  Aging, DNA methylation and cancer. , 1999, Critical reviews in oncology/hematology.

[21]  P. Vertino,et al.  Effects of methylation on expression of TMS1/ASC in human breast cancer cells , 2003, Oncogene.

[22]  C Eng,et al.  Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. , 2001, Human molecular genetics.

[23]  Z. Siegfried,et al.  Spl elements protect a CpG island from de novo methylation , 1994, Nature.

[24]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Groshen,et al.  Progressive increases in de novo methylation of CpG islands in bladder cancer. , 2000, Cancer research.

[26]  J. Minna,et al.  Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells , 2002, Oncogene.

[27]  S. Clark,et al.  Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. , 1997, Nucleic acids research.

[28]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[29]  A. Bird DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[30]  J. Herman,et al.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. , 2002, Cancer research.

[31]  Stephen B. Baylin,et al.  Mapping Patterns of CpG Island Methylation in Normal and Neoplastic Cells Implicates Both Upstream and Downstream Regions inde Novo Methylation* , 1997, The Journal of Biological Chemistry.

[32]  G. Pfeifer,et al.  Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.

[33]  Thomas D. Otto,et al.  Tumour class prediction and discovery by microarray-based DNA methylation analysis , 2002 .

[34]  E. Maher,et al.  Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients , 2003, Oncogene.